Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.01 – $0.95
4% from low
Exchange
OTC Link
OS
Borrow rate
5.04%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $588.9K | $527.4K | $919.1K | $2.1M | $952.1K | $432.5K | $412.6K | $240.5K |
| Cost of revenue | $127.8K | $104.1K | $346.8K | $422.7K | $648.1K | $132.1K | $186.1K | $888.3K |
| Gross profit | $461.1K | $423.4K | $572.3K | $1.7M | $304.0K | $300.4K | $226.5K | −$714.7K |
| Gross margin | 78.3% | 80.3% | 62.3% | 80.3% | 31.9% | 69.4% | 54.9% | -297.2% |
| R&D | $522.9K | $317.3K | $199.3K | $359.3K | $191.1K | $470.7K | $476.9K | $946.3K |
| Operating income | −$1.8M | −$1.3M | −$1.3M | −$184.2K | −$1.5M | −$1.9M | −$2.6M | −$3.6M |
| EBITDA | −$1.7M | −$1.3M | −$1.1M | $185.3K | −$1.1M | −$1.6M | −$2.1M | −$2.3M |
| Net income | −$2.5M | −$2.1M | −$2.0M | −$675.8K | −$1.8M | −$2.7M | −$3.3M | −$4.5M |
| Net margin | -426.1% | -399.4% | -222.5% | -31.5% | -192.4% | -618.6% | -806.2% | -1881.2% |
| EPS (diluted) | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
Annual figures · source: Financial Modeling Prep
MEDMIRA INC
No one on the platform currently holds MMIRF.
No tracked institution reports a position in MMIRF as of their last filing.
No one on the platform has traded MMIRF yet.
| $18M |
| — |
| MDDVFMedical Developments International Limited | $0.37 | +0.00% | $42M | — |
| NVYTFNovacyt S.A. | $0.48 | -0.00% | $35M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 122.8× sales vs its 89.4× historical median P/S.
Fair value ≈ $0.04 · price $0.05 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.